Jacob Walker, MD

A. Switching to DOR/ISL was found to be noninferior to continuing bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) in persons with viral suppression

B. The K65R mutation confers hypersensitivity to ISL and DOR/ISL can be used in the presence of K65R

C. DOR/ISL was non-inferior to BIC/FTC/TAF in persons without prior antiretroviral therapy.

D. ISL has activity against hepatitis B virus (HBV) and therefore no additional treatment is needed when switching to DOR/ISL in people with chronic HBV infection

Jacob Walker, MD

Jacob Walker, MD

Assistant Professor

University of Colorado

Aurora, CO

May 18, 2026: Clinical Considerations for Doravirine/Islatravir